S&P 500 Futures
(0.26%) 5 144.75 points
Dow Jones Futures
(0.29%) 38 551 points
Nasdaq Futures
(0.35%) 17 909 points
Oil
(-0.81%) $83.17
Gas
(1.30%) $1.948
Gold
(-0.06%) $2 345.80
Silver
(0.24%) $27.60
Platinum
(0.89%) $930.30
USD/EUR
(-0.31%) $0.932
USD/NOK
(-0.37%) $10.98
USD/GBP
(-0.40%) $0.797
USD/RUB
(0.25%) $92.11

リアルタイムの更新: Abbott Laboratories [ABL.DE]

取引所: XETRA 産業: Health Care Equipment & Services
最終更新日時27 4月 2024 @ 00:35

1.06% 100.52

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 00:35):

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices...

Stats
本日の出来高 823.00
平均出来高 592.00
時価総額 174.42B
EPS €0 ( 2024-04-17 )
次の収益日 ( €0 ) 2024-07-17
Last Dividend €0.510 ( 2023-07-13 )
Next Dividend €0 ( N/A )
P/E 33.51
ATR14 €0 (0.00%)

Abbott Laboratories 相関

10 最も正の相関
10 最も負の相関

知っていましたか?

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Abbott Laboratories 財務諸表

Annual 2023
収益: €40.11B
総利益: €22.13B (55.18 %)
EPS: €3.28
FY 2023
収益: €40.11B
総利益: €22.13B (55.18 %)
EPS: €3.28
FY 2022
収益: €43.65B
総利益: €24.51B (56.15 %)
EPS: €3.99
FY 2021
収益: €43.08B
総利益: €24.54B (56.97 %)
EPS: €4.00

Financial Reports:

No articles found.

Abbott Laboratories Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
€0.470
(N/A)
€0.470
(N/A)
€0.510
(N/A)
€0.510
(N/A)
€0.510
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)

Abbott Laboratories Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 4.40 - low (46.12%) | Divividend Growth Potential Score: 7.33 - Increase likely (46.66%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend €0.325 2008-01-11
Last Dividend €0.510 2023-07-13
Next Dividend €0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 64 --
Total Paid Out €22.13 --
Avg. Dividend % Per Year 0.00% --
Score 3.9 --
Div. Sustainability Score 4.40
Div.Growth Potential Score 7.33
Div. Directional Score 5.87 --
Next Divdend (Est)
(2024-07-01)
€0 Estimate 22.50 %
Dividend Stability
0.60 Above Average
Dividend Score
3.90
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for XETRA

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
HAW.DE Ex Dividend Junior 2023-06-13 Annually 0 0.00%
RIO1.DE Ex Dividend Knight 2023-08-10 Semi-Annually 0 0.00%
BST.DE Ex Dividend Junior 2023-09-14 Sporadic 0 0.00%
JNJ.DE Ex Dividend Knight 2023-08-25 Quarterly 0 0.00%
TA1.DE Ex Dividend Knight 2023-06-12 Annually 0 0.00%
DEF.DE Ex Dividend Knight 2023-07-24 Annually 0 0.00%
MMM.DE Ex Dividend Junior 2023-08-18 Quarterly 0 0.00%
4I1.DE Ex Dividend Knight 2023-09-26 Quarterly 0 0.00%
VVD.DE Ex Dividend Knight 2023-05-09 Annually 0 0.00%
EVK.DE Ex Dividend Junior 2023-06-01 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.1401.5007.2110.00[0 - 0.5]
returnOnAssetsTTM01.20000[0 - 0.3]
returnOnEquityTTM0.1481.5009.4710.00[0.1 - 1]
payoutRatioTTM0.474-1.0005.26-5.26[0 - 1]
currentRatioTTM00.800-5.00-4.00[1 - 3]
quickRatioTTM00.800-4.71-3.76[0.8 - 2.5]
cashRatioTTM01.500-1.111-1.667[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM22.041.0002.952.95[3 - 30]
operatingCashFlowPerShareTTM3.502.008.8310.00[0 - 30]
freeCashFlowPerShareTTM2.452.008.7710.00[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM0.5521.0004.134.13[0.2 - 0.8]
operatingProfitMarginTTM0.1581.0008.848.84[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM00.800-3.33-2.67[0.5 - 2]
Total Score4.40

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM33.431.0006.720[1 - 100]
returnOnEquityTTM0.1482.509.6610.00[0.1 - 1.5]
freeCashFlowPerShareTTM2.452.009.1810.00[0 - 30]
dividendYielPercentageTTM1.9711.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM3.502.008.8310.00[0 - 30]
payoutRatioTTM0.4741.5005.26-5.26[0 - 1]
pegRatioTTM6.471.50010.000[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1521.0008.710[0.1 - 0.5]
Total Score7.33

Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。